Joined Today: 0

ACCP Access Pharmaceuticals, Stock Message Board

All Messages

ACCP Message Board Home | Join The ACCP Group |

#9: ACCOR: Solid 5.2% Like-For-Like Growth in First-Half 2008 Accor Revenue
TheMachine	July 22, 2008 07:15:43 AM
Strong 5.1% Growth in the Hotels Business, Particularly in France and Germany Very Robust 11.8% Growth in Services Favorable Outlook for Both Services and European Economy... view message ignore post recommend post

#8: Access Pharmaceuticals Demonstrates Ability to Significantly Reduce Glucose Levels in Pre-clinical Testing of Cobalamin(TM) Oral Insulin
FastFun	December 8, 2007 11:20:04 PM
DALLAS, Dec. 7 /PRNewswire-FirstCall/ -- Access Pharmaceuticals, Inc. (OTC Bulletin Board: ACCP) announced today that it has demonstrated the ability, using the company's proprietary... view message ignore post recommend post

#7: Access Pharmaceuticals' ProLindac(TM) to be Featured at the 10th International Symposium on Platinum Coordination Compounds in Cancer Chemotherapy Conference
FastFun	December 8, 2007 11:19:37 PM
DALLAS, Dec. 3 /PRNewswire-FirstCall/ -- Access Pharmaceuticals, Inc. (OTC Bulletin Board: ACCP) announced today that its proprietary therapeutic compound ProLindac will be featured at... view message ignore post recommend post

#6: Access Pharmaceuticals Announces $19.5 Million Recapitalization
FastFun	November 26, 2007 12:17:08 AM
- $9.5 Million Institutional Private Placement - - $10 Million Principal Amount of Debt Exchanged for Convertible Preferred Stock - DALLAS, Nov. 8 /PRNewswire-FirstCall/ -- Access... view message ignore post recommend post

#5: Access Pharmaceuticals Announces Two Poster Presentations Reporting Significant Preclinical Data on ProLindac(TM) at the AACR-NCI-EORTC 'Molecular Targets and Cancer Therapeutics' Conference
FastFun	November 26, 2007 12:15:57 AM
DALLAS, Oct. 29 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP) announced today that two posters describing significant preclinical studies performed by... view message ignore post recommend post

#4: Access Pharmaceuticals Announces Presentation on ProLindac(TM) Phase 2 Study at AACR-NCI-EORTC 'Molecular Targets and Cancer Therapeutics' Conference
FastFun	October 27, 2007 09:20:41 PM
ProLindac Shows Clinically Meaningful Stabilizations and Consistent Early Signs of Anti-Tumor Activity. DALLAS, Oct. 24 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTC... view message ignore post recommend post

#3: Access Pharmaceuticals to Present Data on ProLindac(TM) at the AACR-NCI-EORTC 'Molecular Targets and Cancer Therapeutics' Conference
FastFun	October 27, 2007 09:19:48 PM
DALLAS, Oct. 18 /PRNewswire-FirstCall/ -- Access Pharmaceuticals, Inc. (OTC Bulletin Board: ACCP) announced today that its collaborators will be presenting clinical and preclinical data... view message ignore post recommend post

#2: Access Highlighted in Recent BusinessWeek Article
FastFun	October 7, 2007 06:46:19 AM
Correction - Monday September 17, 9:00 am ET DALLAS--(BUSINESS WIRE)--ACCESS PHARMACEUTICALS, INC. (OTC BB: ACCP - News) announced today that renowned business columnist Gene Marcial of... view message ignore post recommend post

#1: Cancer Drug status
Art	September 18, 2007 03:56:47 PM
ACCP has an excellent potential cancer treatment drug. Any inputs would be appreciated. view message ignore post recommend post

Group Home | Login if you want to post a message